HDAC2 contributes to drug resistance in AML by repressing tumor suppressor genes such as p16INK4a and p21, thereby promoting unchecked cell proliferation and survival (Kim et al., 2013; Zheng et al., 2024). This evidence concerns the gene HDAC2 and acute myeloid leukemia.